Parameters of soluble immune activation in vivo correlate negatively with the proliferative capacity of peripheral blood mononuclear cells in vitro in HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 4, 2009, Pages 354-359

  Schroecksnadel, Katharina ^a   Winkler, Christine ^a   Sarcletti, Mario ^a   Romani, Nikolaus ^a   Banki, Zoltan ^a   Ebner, Susanne ^a   Fuchs, Dietmar ^a   Zangerle, Robert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

HIV IDO; Neopterin; Proliferation; Tryptophan degradation, PBMC

Indexed keywords

CONCANAVALIN A; GAMMA INTERFERON; KYNURENINE; MITOGENIC AGENT; NEOPTERIN; PHYTOHEMAGGLUTININ; POKEWEED MITOGEN; TRYPTOPHAN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; BLOOD; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; STATISTICAL MODEL;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; LYMPHOCYTE ACTIVATION; MALE; NEOPTERIN;

EID: 64249151168     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318198a6e1     Document Type: Article

References (34)

1. Fauci AS. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science. 1988;239:617-622.
2. Silvestri G, Paiardini M, Pandrea I, et al. Understanding the benign nature of SIV infection in natural hosts. J Clin Invest. 2007;117:3148-3154.
3. Letvin NL, Walker BD. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med. 2003;9:861-866.
4. Ciobanu N, Welte K, Kruger G, et al. Defective T-cell response to PHA and mitogenic monoclonal antibodies in male homosexuals with acquired immunodeficiency syndrome and its in vitro correction by interleukin 2. J Clin Immunol. 1983;3:332-340.
5. Hong MA, Wakim VL, Salomao SJ, et al. IL-2 and IFN-gamma, but not IL-4 secretion by peripheral blood mononuclear cells (PBMC) are related to CD4+ T cells and clinical status in Brazilian HIV-I-infected subjects. Rev Inst Med Trop Sao Paulo. 1998;40:351-354.
6. Hofmann B, Lindhardt BO, Gerstoft J, et al. Lymphocyte transformation response to pokeweed mitogen as a predictive marker for development of AIDS and AIDS related symptoms in homosexual men with HIV antibodies. Br Med J (Clin Res Ed). 1987;295:293-296.
7. Hofmann B, Jakobsen KD, Odum N, et al. HIV-induced immunodeficiency. Relatively preserved phytohemagglutinin as opposed to decreased pokeweed mitogen responses may be due to possibly preserved responses via CD2/phytohemagglutinin pathway. J Immunol. 1989;142:1874-1880.
8. Miedema F. Immunological abnormalities in the natural history of HIV infection: mechanisms and clinical relevance. Immunodefic Rev. 1992;3: 173-193.
9. Bansal AS, Moran A, Potter M, et al. Lymphocyte transformation responses to Phytohamagglutinin and pokeweed mitogen in patients at differing stages of HIV infection: are they worth measuring? J Clin Pathol. 1993;46:846-848.
10. Roos MT, Miedema F, Koot M, et al. T cell function in vitro is an independent progression marker for AIDS in human immunodeficiency virus-infected asymptomatic subjects. J Infect Dis. 1995;171:531-536.
11. Hazenberg MD, Stuart JW, Otto SA, et al. T-cell division in human immunodeficiency virus (HIV)-I infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood. 2000;95:249-255.
12. Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17:1881-1888.
13. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534-1543.
14. Anthony KB, Yoder C, Metcalf JA, et al. Incomplete CD4 T cell recovery in HIV-I infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. JAcquir Immune Defic Syndr. 2003;33:125-133.
15. Mildvan D, Bosch RJ, Kim RS, et al. Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis. 2004;189:1811-1820.
16. Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990;322:166-172.
17. Liu Z, Cumberland WG, Hultin LE, et al. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:83-92.
18. Zangerle R, Steinhuber S, Sarcletti M, et al. Serum HIV-I RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-I-infected individuals. Int Arch Allergy Immunol. 1998;116:228-239.
19. Giorgi JV Lyles RH, Matud JL, et al. Predictive value of immunologic and virologie markers after long or short duration of HIV-I infection 4. J Acquir Immune Defic Syndr. 2002;29:346-355.
20. Mildvan D, Spritzler J, Grossberg SE, et al. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-I infection. Clin Infect Dis. 2005;40:853-858.
21. Wirleitner B, Schroecksnadel K, Winkler C, et al. Neopterin in HIV-I infection. Mol Immunol. 2005;42:183-194.
22. Zangerle R, Widner B, Quirchmair G, et al. Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-I infection. Clin Immunol. 2002;104:242-247.
23. Mellor AL, Munn D, Chandler P, et al. Tryptophan catabolism and T cell responses. Adv Exp Med Biol. 2003;527:27-35.
24. Rudy T, Opelz G, Gerlach R, et al. Correlation of in vitro immune defects with impaired gamma interferon response in human-immunodeficiencyvirus-infected individuals. Vox Sang. 1988;54:92-95.
25. Fuchs D, Shearer GM, Boswell RN, et al. Increased serum neopterin in patients with HIV-I infection is correlated with reduced in vitro interleukin-2 production. Clin Exp Immunol. 1990;80:44-48.
26. Widner B, Werner ER, Schennach H, et al. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem. 1997;43:24242426.
27. + T cells and is reversed by allowing T cells to rest in culture: arguments for in vivo CD4+ T cell activation. Clin Immunol Immunopathol. 1993;67:185-191.
28. Kaur A, Grant RM, Means RE, et al. Diverse host responses and outcomes following simian immunodeficiency virus SIVmac239 infection in sooty mangabeys and rhesus macaques. J Virol. 1998;72:9597-9611.
29. Chakrabarti LA, Lewin SR, Zhang L, et al. Normal T-cell turnover in sooty mangabeys harboring active simian immunodeficiency virus infection. J Virol. 2000;74:1209-1223.
30. Goicoechea M, Smith DM, Liu L, et al. Determinants of CD4- T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-I DNA. J Infect Dis. 2006;194:29-37.
31. Benito JM, Lopez M, Lozano S, et al. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2005;38:373-381.
32. Grabar S, Le My Goujard C, et al. Clinical outcome of patients with HIV-I infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000; 133:401-410.
33. Pakker NG, Roos MT, van Leeuwen R, et al. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 16:318-326.
34. Wirleitner B, Obermoser G, Bock G, et al. Induction of apoptosis in human blood T cells by 7,8-dihydroneopterin: the difference between healthy controls and patients with systemic lupus erythematosus. Clin Immunol. 2003;107:152-159.